Panobacumab (KBPA101) 是一种完全人 IgM/κ 单克隆抗体，由人类B淋巴细胞产生，对血清型 O11P. aeruginosa的 LPS O 多糖具有抗性。
| 生物活性 | Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 ofP. aeruginosa[1]. |
体外研究
(In Vitro) | Panobacumab (KBPA101) strongly binds to 18 of 20 clinical O11 isolates, functional avidity of KBPA101 to O11 LPS determined by inhibition ELISA is 5.81×107M-1± 2.8×107M-1[1].
Panobacumab (KBPA101) (0.0001-100 ng/mL; 2 h) specifically mediates complement-dependent opsonophagocytosis ofP. aeruginosaserotype O11 with an IC50of 0.16 ng/mL[1].
Panobacumab (KBPA101) (0.1-10 ng/mL) shows direct complement-dependent killing ofP. aeruginosaserotype O11 cells in a dose-dependent manner[1].
|
体内研究
(In Vivo) | Panobacumab (KBPA101) (1-4 mg/kg; i.v.; once) protects mice from systemic infection withP. aeruginosaserotype O11 in a murine burn wound model[1].
Panobacumab (KBPA101) (0.005-0.4 mg/kg; i.v.; once) protects mice from local lung infection withP. aeruginosaserotype O11 in an acute lung infection model[1].
| Animal Model: | Female NMRI mice, murine burn wound model[1] | | Dosage: | 1, 2, or 4 mg/kg | | Administration: | Intravenous injection, single dose | | Result: | Significantly reduced mortality compared to untreated control animals administered either immediately or 4 h postchallenge. |
| Animal Model: | BALB/c mice, acute lung infection model[1] | | Dosage: | 0.005 to 0.4 mg/kg | | Administration: | Intravenous injection, single dose | | Result: | Led to rapid clearance ofP. aeruginosafrom the lung, completely cleared systemicP. aeruginosafrom the spleen, whereas live bacteria were still present in untreated mice at 48 h postchallenge, showed milder macroscopic lung pathology at 6 and 24 h after infection. |
|
| Clinical Trial | |
| CAS 号 | |
| 中文名称 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
